Advancing Drug Discovery via M-Optimus
Bioptimus Launches STELA Spatial Biology Atlas
Partnership with 10x Genomics aims to profile 100,000 specimens to accelerate drug discovery and precision medicine.

Digital visualization of spatial biology tissue mapping with complex molecular data overlays in a modern laboratory environment.
Photo: Avantgarde News
Bioptimus has announced the launch of the Spatial Tissue Embedding Learning Atlas, known as STELA, marking a significant milestone in precision medicine [1]. This multinational initiative is a collaborative effort with 10x Genomics and Broad Clinical Labs [2]. The project aims to profile 100,000 patient specimens to build a comprehensive biological dataset [3]. The gathered data will power M-Optimus, a multimodal "world model" of biology designed to enhance drug discovery processes [1][3]. By linking clinical data with spatial biology, the partners intend to accelerate the development of new treatments [2]. This initiative represents the world's largest clinically linked spatial biology atlas currently in development [3].
Editorial notes
Transparency note
Drafted with LLM; human-edited
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
- 1.↗
streetinsider.com
https://www.streetinsider.com/Corporate+News/Bioptimus+launches+STELA+spatial+biology+atlas+with+10x+Genomics+partnership/26213063.html
- 2.↗
investing.com
https://www.investing.com/news/company-news/bioptimus-launches-spatial-biology-atlas-with-10x-genomics-93CH-4579486
- 3.↗
stocktitan.net
https://www.stocktitan.net/news/TXG/bioptimus-announces-stela-the-world-s-largest-clinically-linked-9iyvose8uhyl.html
Related stories
View allTopics
About the author
Avantgarde News Desk covers advancing drug discovery via m-optimus and editorial analysis for Avantgarde News.


